Ivan Kopljar1, An De Bondt2, Petra Vinken1, Ard Teisman1, Bruce Damiano3, Nick Goeminne1, Ilse Van den Wyngaert2, David J Gallacher1, Hua Rong Lu1. 1. Preclinical Development and Safety, Discovery Sciences, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium. 2. Computational Sciences, Discovery Sciences, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium. 3. Preclinical Safety and Development, Discovery Sciences, Janssen Research and Development, Janssen Pharmaceutica NV, Spring House, PA, USA.
Abstract
BACKGROUND AND PURPOSE: In the pharmaceutical industry risk assessments of chronic cardiac safety liabilities are mostly performed during late stages of preclinical drug development using in vivo animal models. Here, we explored the potential of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) to detect chronic cardiac risks such as drug-induced cardiomyocyte toxicity. EXPERIMENTAL APPROACH: Video microscopy-based motion field imaging was applied to evaluate the chronic effect (over 72 h) of cardiotoxic drugs on the contractile motion of hiPS-CMs. In parallel, the release of cardiac troponin I (cTnI), heart fatty acid binding protein (FABP3) and N-terminal pro-brain natriuretic peptide (NT-proBNP) was analysed from cell medium, and transcriptional profiling of hiPS-CMs was done at the end of the experiment. KEY RESULTS: Different cardiotoxic drugs altered the contractile motion properties of hiPS-CMs together with increasing the release of cardiac biomarkers. FABP3 and cTnI were shown to be potential surrogates to predict cardiotoxicity in hiPS-CMs, whereas NT-proBNP seemed to be a less valuable biomarker. Furthermore, drug-induced cardiotoxicity produced by chronic exposure of hiPS-CMs to arsenic trioxide, doxorubicin or panobinostat was associated with different profiles of changes in contractile parameters, biomarker release and transcriptional expression. CONCLUSION AND IMPLICATIONS: We have shown that a parallel assessment of motion field imaging-derived contractile properties, release of biomarkers and transcriptional changes can detect diverse mechanisms of chronic drug-induced cardiac liabilities in hiPS-CMs. Hence, hiPS-CMs could potentially improve and accelerate cardiovascular de-risking of compounds at earlier stages of drug discovery. LINKED ARTICLES: This article is part of a themed section on New Insights into Cardiotoxicity Caused by Chemotherapeutic Agents. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.21/issuetoc.
BACKGROUND AND PURPOSE: In the pharmaceutical industry risk assessments of chronic cardiac safety liabilities are mostly performed during late stages of preclinical drug development using in vivo animal models. Here, we explored the potential of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) to detect chronic cardiac risks such as drug-induced cardiomyocyte toxicity. EXPERIMENTAL APPROACH: Video microscopy-based motion field imaging was applied to evaluate the chronic effect (over 72 h) of cardiotoxic drugs on the contractile motion of hiPS-CMs. In parallel, the release of cardiac troponin I (cTnI), heart fatty acid binding protein (FABP3) and N-terminal pro-brain natriuretic peptide (NT-proBNP) was analysed from cell medium, and transcriptional profiling of hiPS-CMs was done at the end of the experiment. KEY RESULTS: Different cardiotoxic drugs altered the contractile motion properties of hiPS-CMs together with increasing the release of cardiac biomarkers. FABP3 and cTnI were shown to be potential surrogates to predict cardiotoxicity in hiPS-CMs, whereas NT-proBNP seemed to be a less valuable biomarker. Furthermore, drug-induced cardiotoxicity produced by chronic exposure of hiPS-CMs to arsenic trioxide, doxorubicin or panobinostat was associated with different profiles of changes in contractile parameters, biomarker release and transcriptional expression. CONCLUSION AND IMPLICATIONS: We have shown that a parallel assessment of motion field imaging-derived contractile properties, release of biomarkers and transcriptional changes can detect diverse mechanisms of chronic drug-induced cardiac liabilities in hiPS-CMs. Hence, hiPS-CMs could potentially improve and accelerate cardiovascular de-risking of compounds at earlier stages of drug discovery. LINKED ARTICLES: This article is part of a themed section on New Insights into Cardiotoxicity Caused by Chemotherapeutic Agents. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.21/issuetoc.
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: D J DeAngelo; A Spencer; K N Bhalla; H M Prince; T Fischer; T Kindler; F J Giles; J W Scott; K Parker; A Liu; M Woo; P Atadja; K K Mishra; O G Ottmann Journal: Leukemia Date: 2013-02-06 Impact factor: 11.528
Authors: Elizabeth Fox; Bassem I Razzouk; Brigitte C Widemann; Shaun Xiao; Michelle O'Brien; Wendy Goodspeed; Gregory H Reaman; Susan M Blaney; Anthony J Murgo; Frank M Balis; Peter C Adamson Journal: Blood Date: 2007-10-24 Impact factor: 22.113
Authors: Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang Journal: Genome Biol Date: 2004-09-15 Impact factor: 13.583
Authors: Mahnaz Maddah; Julia D Heidmann; Mohammad A Mandegar; Chase D Walker; Sara Bolouki; Bruce R Conklin; Kevin E Loewke Journal: Stem Cell Reports Date: 2015-03-19 Impact factor: 7.765
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; William A Catterall; John A Cidlowski; Anthony P Davenport; Doriano Fabbro; Grace Fan; John C McGrath; Michael Spedding; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Hua Rong Lu; Haoyu Zeng; Ralf Kettenhofen; Liang Guo; Ivan Kopljar; Karel van Ammel; Fetene Tekle; Ard Teisman; Jin Zhai; Holly Clouse; Jennifer Pierson; Michael Furniss; Armando Lagrutta; Frederick Sannajust; David J Gallacher Journal: Toxicol Sci Date: 2019-08-01 Impact factor: 4.849
Authors: Jaecheol Lee; Ning-Yi Shao; David T Paik; Haodi Wu; Hongchao Guo; Vittavat Termglinchan; Jared M Churko; Youngkyun Kim; Tomoya Kitani; Ming-Tao Zhao; Yue Zhang; Kitchener D Wilson; Ioannis Karakikes; Michael P Snyder; Joseph C Wu Journal: Cell Stem Cell Date: 2018-03-01 Impact factor: 24.633
Authors: Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu Journal: Circ Res Date: 2019-09-19 Impact factor: 17.367
Authors: Ivan Kopljar; An De Bondt; Petra Vinken; Ard Teisman; Bruce Damiano; Nick Goeminne; Ilse Van den Wyngaert; David J Gallacher; Hua Rong Lu Journal: Br J Pharmacol Date: 2017-02-08 Impact factor: 8.739
Authors: Ivan Kopljar; Hua Rong Lu; Karel Van Ammel; Martin Otava; Fetene Tekle; Ard Teisman; David J Gallacher Journal: Stem Cell Reports Date: 2018-12-11 Impact factor: 7.765